SAB Biotherapeutics Inc (SABS NASDAQ) stock market data APIs
$4.1356
0.06(1.5%)
as of February 12, 2026
Try our APIs with
free plan!
SAB Biotherapeutics Inc Financial Data Overview
Price chart is built with
Anychart
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Prev. Close
4.1356
Open
4.1985
High
4.2866
Low
4.043
52 wk Range
1-4.68
Market Cap
199 M
Shares Outstanding
47 607 K
Revenue
115 K
EPS
-0.21
Beta
0.596
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get SAB Biotherapeutics Inc data using free add-ons & libraries
Get SAB Biotherapeutics Inc Fundamental Data
SAB Biotherapeutics Inc Fundamental data includes:
- Net Revenue: 115 K
- EBITDA: -40 087 972
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-14
- EPS/Forecast: -0.12
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
SAB Biotherapeutics Inc News
New
Analysts Predict Up to 400% Spike for These 2 ‘Strong Buy’ Penny Stocks
While mega-cap tech stocks with trillion-dollar valuations tend to dominate market headlines, they aren’t the only games in town. Smaller companies, especially those at the low end of the price spec...
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinic...
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
SAB Biotherapeutics, Inc. MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin ...
SAB BIO Announces Positive Confirmatory Clinical Results from the Phase 1 Study of SAB-142 in Development for the Treatment of Stage 3 T1D
Phase 1 data confirms SAB-142 does not cause serum sickness and has low/no immunogenicity at any dose and in all cohorts, including redosed healthy volunteers Study results support the chronic dosing ...
Get SAB Biotherapeutics Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
